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Abstract
Efforts to develop gene therapies for hearing loss have been hampered by the lack of safe, 
efficient, and clinically relevant delivery modalities1, 2. Here we demonstrate the safety and 
efficiency of Anc80L65, a rationally designed synthetic vector3, for transgene delivery to the 
mouse cochlea. Cochlear explants incubated with Anc80L65 encoding eGFP demonstrated high 
level transduction of inner and outer hair cells (60–100%). Injection of Anc80L65 through the 
round window membrane resulted in highly efficient transduction of inner and outer hair cells, a 
substantial improvement over conventional adeno-associated virus (AAV) vectors. Anc80L65 
round window injection was well tolerated, as indicated by sensory cell function, hearing and 
vestibular function, and immunologic parameters. The ability of Anc80L65 to target outer hair 
cells at high rates, a requirement for restoration of complex auditory function, may enable future 
gene therapies for hearing and balance disorders.
Hearing loss is the most common sensory disorder worldwide, with half of pre-lingual 
deafness due to genetic causes4. More than 300 genetic loci linked to hereditary hearing loss 
and >100 causative genes have also been identified4, 5. Age-related hearing impairment 
affects the quality of life of over a quarter of individuals over 65 years old. While medication 
history and noise exposure are known contributing factors to presbycusis, several genetic 
factors have been identified6. Sensory cells of the adult mammalian cochlea lack the 
capacity for self-renewal7, 8. Current therapies for hearing loss employ various strategies 
depending on the level and exact position of impairment, including sound amplification 
(hearing aids), enhanced sound transmission (middle ear prostheses/active implants), and 
direct neuronal stimulation (cochlear implants) to compensate for permanent damage to 
primary sensory hair cells or to spiral ganglion neurons, which form the auditory nerve and 
relay acoustic information to the brain2. These approaches, while transformative, remain far 
from optimal in restoring complex hearing function and may have deficiencies in frequency 
sensitivity, natural sound perception, and speech discrimination in noisy environments.
Therapeutic gene transfer to the cochlea could improve on the current standard of care for 
both genetic1, 2, 9–13 and age-related or environmentally induced hearing loss1, 2, 12, 13. This 
approach would require the development of methods for safe, efficient delivery of transgene 
constructs to the relevant cell types in the organ of Corti in the cochlea. The organ of Corti 
includes two classes of sensory hair cells: inner hair cells (IHCs), which convert mechanical 
information carried by sound into electrical signals transmitted to neuronal structures, and 
outer hair cells (OHCs), which amplify and tune the cochlear response, a process required 
for complex hearing function14. Other potential targets in the inner ear include spiral 
ganglion neurons, columnar cells of the spiral limbus, which are important for the 
maintenance of the adjacent tectorial membrane15–17, and supporting cells, which have 
protective functions and can be triggered to transdifferentiate into hair cells up to an early 
neonatal stage18–21.
Direct access to hair cells for gene therapy may be achievable through vector injection into 
the cochlear duct. However, interventions that alter the delicate high-potassium endolymph 
fluid in the duct could disrupt the endocochlear potential, leading to damage of the sensory 
cells and irreversible hearing loss. The perilymph-filled spaces surrounding the cochlear 
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duct, scala tympani and scala vestibuli can be accessed from the middle ear, either through 
the oval window membrane or the round window membrane (RWM). The RWM, which is 
the only non-bony opening into the inner ear, is relatively easily accessible in many animal 
models, and administration of viral vector using this route has been well tolerated10, 11, 22. In 
humans, cochlear implant placement routinely relies on surgical electrode insertion through 
the RWM23.
Several non-viral24, 25 and viral (e.g., adenovirus, AAV, lentivirus, herpes simplex virus I, 
vaccinia virus) gene transfer vectors have been tested in the cochlea often with only transient 
or suboptimal gene transfer as a result1. Only adenovirus to date has progressed to a clinical 
program (NCT02132130)2, 26. For other target organs, such as the liver and the retina, AAV 
has shown clinical efficacy and safety in hemophilia B27, two types of inherited 
blindness28, 29, and familial lipoprotein lipase deficiency30. Previous studies of AAV 
serotypes in vivo inner ear injection via different routes of administration highlighted the 
difficulties in targeting OHCs, particularly via RWM injection31, and resulted in only partial 
rescue of hearing in mouse models of inherited deafness9–11. To identify vectors that target 
both IHCs and OHCs with high efficiency, we evaluated natural AAVs, alongside a recently 
developed synthetic AAV called Anc80L65. The latter in silico designed particle 
approximates the ancestral state of the viral capsid within the lineage of the commonly used 
AAV serotypes 1, 2, 6, 8, and 9 and is a structurally stable and antigenically distinct AAV3. 
Importantly, Anc80L65 was shown to be a potent gene transfer agent in liver, retina, and 
muscle, which led us to characterize its tropism in the inner ear in vivo.
Results
In a first selection, we incubated iodixanol-purified high-titer preparations of single-stranded 
AAV1, 2, 6, 8, 9, and Anc80L65 encoding eGFP driven from the cytomegalovirus 
immediate-early (CMV) promoter, at equal doses of 1010 genome-containing (GC) particles, 
with organotypic cochlear explants from C57BL/6 or CBA/CaJ mice harvested at postnatal 
day (P) P4. We performed histology of the inoculated cochleas after 2 days of vector 
exposure. The results in Fig. 1 and Supplementary Fig. 1 illustrate the tropism of the five 
conventional AAV serotypes and Anc80L65 as monitored by eGFP expression in C57BL/6 
and CBA/CaJ, respectively. eGFP expression was qualitatively brighter in cochlear cultures 
exposed to Anc80L65, with expression apparent in many cochlear cell types (Fig. 1 and 
Supplementary Fig. 1). Morphometric quantitative analysis was performed to determine 
transduction rates for IHCs, OHCs, supporting cells, limbus cells, and spiral ganglion 
neurons. For IHCs and OHCs, vector transduction efficiency was quantified as the 
percentage of eGFP-positive cells in representative 100 micron sections taken from the basal 
and apical regions of the cochlea. Anc80L65 targeted IHCs and OHCs at efficiencies 
between 60 and 100% in apical and basal regions of both mouse strains tested (Fig. 1H, I 
and Supplementary Fig. 1G, H). Anc80L65 demonstrated consistently and qualitatively 
brighter IHC and OHC eGFP expression as compared to AAV2 (Fig. 1 and Supplementary 
Fig. 1).
To control for possible differences between the AAV serotypes in the onset of transgene 
expression, which could lead to an underestimate of expression at the 2-day time point, we 
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repeated the above experiment with a new set of cochleas and maintained the culture for an 
additional 5 days (referred to as 48h+5d). A similar pattern of expression in IHCs and OHCs 
was observed in this longer-term study for AAV2 and Anc80L65 (Fig. 1J, K and 
Supplementary Fig. 1I, J). Moderate increases in expression for AAV6, 8, and 9 in CBA/CaJ 
mice, particularly at the basal turn (Fig. 1J, K, and Supplementary Fig. 1I, J), were noted. 
Other cell types were targeted by all serotypes, with limbus being more permissive than 
supporting cells, followed by spinal ganglion neurons (Supplementary Fig. 2, 3, and 4). 
Consistently, Anc80L65 transduction yielded higher efficiencies and stronger expression, 
evidenced by brighter eGFP fluorescence (Fig. 1 and Supplementary Fig. 1–4).
Next, we evaluated the tropism and gene transfer efficiency of AAV1, 2, 6, 8, and Anc80L65 
in vivo, using a protocol that is therapeutically relevant with respect to vector 
pharmacokinetics, anatomical and cellular barriers to transduction, and surgical approach. 
C57BL/6 animals were injected at P1 and cochleas were harvested, fixed and stained at P10. 
Consistent with prior reports9–11, 32, AAV1 transduced IHCs with moderate to high 
efficiency (Fig. 2A, B). Our results indicated that AAV2, 6, and 8 target low numbers of 
IHCs (Fig. 2A, B). Also, consistent with prior reports, transduction of OHCs was minimal 
(<5%) for all conventional AAV serotypes tested. In contrast, Anc80L65 transduced nearly 
100% of IHCs and ~90% of OHCs (Fig. 2A–C) at a 20- (for AAV1) to 3-fold (for AAV2) 
lower dose. Transduction at equal dose of 1.36 × 1012 GC for all serotypes resulted in 
substantial IHC and OHC transduction for Anc80L65, but minimal IHC targeting for AAV1, 
2, and 8, and none noted in OHCs as observed by live-cell imaging by epifluorescence 
microscopy (Fig. 3C, D).
The Anc80L65-transduced samples were subsequently fixed, stained and imaged, revealing 
a dose-dependence of hair cell transduction (Fig. 3E). The unprecedented high level of OHC 
targeting (Fig. 2C, Fig. 3) suggests that the transduction mechanism of Anc80L65 is 
qualitatively different from that of other AAVs. We found similar levels of Anc80L65 
transduction throughout the cochlea from base to apex in a total of three Anc80L65-injected 
mice (Fig. 2A, B, C). Low-magnification views of the cochlear apex (Fig. 3A) show strong 
eGFP expression far from the injection site. High-magnification images of the base reveal 
100% IHC and 95% OHC transduction (Fig. 3B).
In some animals, we found robust eGFP expression in the contralateral uninjected ear 
(Supplementary Fig. 5). In mice, the cochlear aqueduct is patent, providing a fluid path from 
the cochlear perilymph into the cerebrospinal fluid, the contralateral aqueduct and into the 
contralateral cochlea. We therefore investigated whether Anc80L65-eGFP injected via the 
RWM transduced neurons in the brain. Cross-sections of the cerebellum revealed strong 
eGFP expression in cerebellar Purkinje neurons (Supplementary Fig. 6A, B).
We further investigated whether Anc80L65 RWM injection led to a humoral response to the 
vector capsid and found that low neutralization to vector was detectable in injected mice in 
serum, but not in cerebrospinal fluid, at the level of sensitivity of the assay and sampling 
(Supplementary Fig. 6C).
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To determine whether Anc80L65-eGFP had any consequences for cellular function, we 
recorded sensory transduction currents from both IHCs and OHCs. Representative currents 
evoked by hair bundle deflections from P7 OHCs and P35 IHCs revealed no differences in 
amplitude, sensitivity or kinetics, between eGFP-positive and eGFP-negative control cells 
(Fig. 2D). We recorded from 51 eGFP-positive and 52 eGFP-negative hair cells from all 
regions of the cochlea and ages between one and five weeks after exposure to Anc80L65. 
Responses were indistinguishable from wild-type in all cases (Fig. 2E), which confirmed 
that Anc80L65 transduction had no detrimental effects on sensory cell function.
To evaluate systems level function, we measured auditory brainstem responses (ABRs) from 
four Anc80L65-injected ears and four uninjected ears. Minimal sound thresholds required to 
evoke ABRs were plotted (Fig. 2F) and revealed no difference in threshold between injected 
and uninjected ears. Histological analysis showed strong eGFP fluorescence in all four 
injected ears (data not shown). In one additional case, there were no eGFP-positive cells and 
ABR thresholds were elevated (Fig. 2F), suggesting that the injection failed and that the 
needle may have breached the cochlear duct and caused permanent damage.
As a final test of auditory function, we measured distortion product otoacoustic emissions 
(DPOAEs), which is an assay for proper cochlear amplification and tuning and is a sensitive 
measure of OHC viability17. Despite robust OHC transduction by Anc80L65-eGFP, we 
found no difference in DPOAE thresholds relative to uninjected control ears (Fig. 2G). Thus, 
data from all three measures---single cell physiology, ABRs, and DPOAEs---indicate that 
RWM injection, Anc80L65 transduction and eGFP expression in IHCs and OHCs are safe 
and do not harm auditory function.
Since the perilymphatic solutions of the cochlea are continuous with those of the vestibular 
labyrinth, we wondered whether Anc80L65-eGFP injected via the cochlear RWM would 
transduce vestibular sensory organs. Indeed, whole-mounts of vestibular epithelia revealed 
robust eGFP expression in both type I and type II hair cells of the utricle, a vestibular organ 
sensitive to gravity and linear head movements and in the semicircular canals, which are 
sensitive to rotational head movements (Fig. 4A, B). To address the safety concern that 
Anc80L65 transduction may affect balance, we used the rotarod test for vestibular function. 
Injected mice performed similarly to uninjected controls (P = 1.00, Supplementary Fig. 7).
Some forms of genetic deafness also cause vestibular dysfunction, and Anc80L65 may be a 
useful vector for gene delivery into human vestibular organs. To investigate this possibility, 
we harvested human vestibular epithelia from four adult patients undergoing resection of 
vestibular schwannoma tumors and placed the sensory epithelium in culture as previously 
described33. Figure 4C reveal for AAV-transduced samples strong eGFP fluorescence 
throughout the human vestibular epithelium in both hair cells and supporting cells. A high-
magnification view in an epithelium counterstained with Myo7A in Figure 4D revealed that 
83% (19/23) of Myo7A-positive hair cells were also eGFP-positive, suggesting that 
Anc80L65 can transduce both mouse and human hair cells efficiently.
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Discussion
Our finding that Anc80L65 transduces OHCs with high efficiency overcomes the low 
transduction rates that have limited development of cochlear gene therapy using 
conventional AAV serotypes. Thus, Anc80L65 may provide a valuable approach for gene 
delivery to human IHCs and OHCs, as well as to other inner ear cell types that are 
compromised by genetic hearing and balance disorders. Previous work has shown that 
Anc80L65 has an analogous safety profile in mouse and nonhuman primate after systemic 
injection, and is antigenically distinct from circulating AAVs, providing a potential benefit 
in terms of pre-existing immunity, which limits the efficacy of conventional AAV vectors4.
Further validation of Anc80L65 as a gene transfer vector for use in human inner ear gene 
therapy will require targeting efficiency studies in large-animal models; additional 
exploration of the window of opportunity for therapeutic intervention; and pharmacology 
and toxicology studies to investigate the safety of Anc80L65 upon cochlear administration. 
Given the promiscuity of expression of AAV, including Anc80L65, additional methods to 
maximize specificity and minimize biodistribution should be considered to limit expression 
outside of the therapeutic cochlear cell target. Considering that nonsyndromic auditory and 
vestibular dysfunction can be caused by dominant or recessive mutations in >100 genes, 
Anc80L65 may accelerate the development of novel gene therapy strategies for a wide range 
of inner ear disorders.
Online Methods
Animal models and general methods
All experiments were approved by the respective Institutional Animal Care and Use 
Committees at Massachusetts Eye and Ear (protocol #15-003) and Boston Children’s 
Hospital (protocol #12-02-2146) as well as the Institutional Biosafety Committee (protocol 
#IBC-P00000447). Wild-type C57BL/6J and CBA/CaJ mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME) and animals of either sex were used for experimentation in an 
estimated 50/50 ratio. Group sizes per experiment for the in vitro and in vivo transduction 
assays and subsequent endpoints were determined by access to specimen and technical 
feasibility. Reported observations on Anc80L65 transduction were qualitatively validated in 
subsequent experiments with various vector lots (except for the human vestibular tissue 
transduction due to the unique and limited nature of access to specimen). No statistical 
analysis between serotype transduction efficiencies was performed due to the limited access 
to specimen and qualitative nature of the reported findings.
Viral vectors
AAV2/1, 2/2, 2/6, 2/8, 2/9, and AAV2/Anc80L65 with a CMV-driven eGFP transgene and 
the Woodchuck hepatitis virus Post-transcriptional Regulatory Element (WPRE) cassette 
were prepared at Gene Transfer Vector Core (vector.meei.harvard.edu) at Massachusetts Eye 
and Ear as previously described3. AAV2/Anc80L65 plasmid reagents are available through 
addgene.com.
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In vitro explant cultures
A total of 156 cochlear explant cultures from mouse pups of both strains were prepared on 
postnatal day 434. In brief, murine temporal bones were harvested after decapitation and the 
cochlea was dissected to culture as organotypic explants connected to the spiral ganglion 
neuron region. Two specimens were obtained per cochlea, one (“apical”) consisting of the 
lower apical and one (“basal”) of the upper basal turn. For each serotype, a minimum of 3 
(CBA/CaJ, 48h), 2 (CBA/CaJ, 48h+5d), 3 (C57BL/6, 48h), 2 (C57BL/6, 48h+5d) basal and 
apical specimens were inoculated. Specimens were excluded if cochlear morphology was 
not retained during the culture. Sample numbers were chosen to inform on the variability of 
transduction and to provide a basis for selection for further in vivo evaluation. Explants were 
incubated with culture medium (98% Dulbecco’s Modified Eagle Medium (DMEM), 1% 
ampicillin, and 1% N2 supplement during the first 12 hours, plus 1% fetal bovine serum 
(FBS)) and 1010 GC of AAV for 48h in 50 μl. For the 48h+5d condition, the medium with 
AAV was replaced with fresh media without AAV for an additional 5 days.
Human vestibular epithelia from utricles obtained from four consented, adult patients 
undergoing vestibular schwannoma tumor resection were cultured as previously described33, 
exposed to 1010 GC AAV for 24 hours and maintained in culture for 10 days after which the 
tissue was fixed and stained with phalloidin and imaged. Studies were approved by the 
Surrey Borders NRES Committee London (Health Research Authority) under reference 
number 11/LO/0475.
In vivo injections
Mouse pups (P0 to P2) were injected via the round window membrane (RWM) using 
beveled glass microinjection pipettes. Pipettes were pulled from capillary glass (WPI, 
Sarasota, FL) on a P-2000 pipette puller (Sutter Instrument, Novato, CA) and were beveled 
(~20 μm tip diameter at a 28° angle) using a micropipette beveler (Sutter Instrument, 
Novato, CA). EMLA cream (lidocaine 2.5% and prilocaine 2.5%) was applied externally for 
analgesia using sterile swabs to cover the surgical site (left mastoid prominence). Body 
temperature was maintained on a 38 °C warming pad prior to surgery. Pups were 
anesthetized by rapid induction of hypothermia into ice/water for 2–3 minutes until loss of 
consciousness, and this state was maintained on a cooling platform for 5–10 minutes during 
the surgery. The surgical site was disinfected by scrubbing with Betadine and wiping with 
70% Ethanol in repetition three times. A post-auricular incision was made to expose the 
transparent otic bulla, a micropipette was advanced manually through the bulla and 
overlying fascia, and the RWM was penetrated by the tip of the micropipette. Approximately 
1 μL of virus at the available concentration was injected unilaterally within 1 min into the 
left ear manually in 5 (AAV1), 4 (AAV2), 2 (AAV8), 1 (AAV6), 3 (Anc80L65) C57BL/6 
animals and quantification was performed on a representative specimen per vector. In order 
to control for factors related to the specific vector preparation such as quality and purity, 
Anc80L65 results were confirmed in subsequent studies with different vector lots from 
independent preparation which were confirmatory of our qualitative findings presented here 
(data not shown). Injections were performed per group in a non-blinded fashion. 
Occasionally, the injection needle was inserted too deep, too shallow or at the wrong angle. 
If there was visible damage to the middle or inner ear structures, the samples were excluded 
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from further analysis. Success rates of injection ranged between ~50% to ~80% depending 
on the experience level of the injector. After the injection, the skin incision was closed using 
a 6-0 black monofilament suture (Surgical Specialties, Wyomissing, PA). Pups were 
subsequently returned to the 38 °C warming pad for 5–10 min and then put back to their 
mother for breeding.
Hearing tests
Auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) 
data were collected as described previously10. Stimuli tested in anesthetized mice varied 
between 10 and 90 dB sound pressure level at frequencies of 5.6, 8, 11.3, 16, 22.6, and 32 
kHz. Four Anc80L65-injected ears, four uninjected ears, and one negative control ear with 
injection damage without eGFP fluorescence were analyzed at P28-P30.
Cerebrospinal fluid and blood sampling
Cerebrospinal fluid (CSF) sampling from the cisterna magna35 and intracardiac blood 
collection with thoracotomy were performed in a terminal procedure. Through the 
microcapillary tube, the maximum amount (up to 5 μL) of clear CSF per animal was 
collected in a volume of 60 μL PBS, leading to slightly different starting dilutions that 
subsequently were standardized with additional control PBS prior to the start of the 
experiment. After obtaining the blood sample in a 1.1 mL Z-Gel micro tube (Sarstedt, 
Nümbrecht, Germany), it was spun down at 8,000 rpm for 8 minutes and serum was stored 
together with the CSF sample (in PBS) at −80 °C until further use.
Histological analysis
After a follow-up period of 5 to 29 days, animals were sacrificed and cochlear whole-mounts 
were prepared as previously reported36. Both cochlear whole-mounts and explants were 
stained with antibodies against myosin 7A (Myo7A, #25-6790 Proteus Biosciences, 
Ramona, CA, 1:400) and β-tubulin (TuJ1, #MMS-435P Biolegend, San Diego, CA, 1:200), 
together with corresponding secondary antibodies (Alexa Fluor 555 anti-mouse and Alexa 
Fluor 647 anti-rabbit, #A-21422 and #A-21245 Thermo Fisher Scientific, Waltham, MA, 
1:1000)34. Mounting of the specimens was followed by confocal microscopy. Every image 
of a given experimental series was obtained with the same settings, with laser intensity being 
chosen based on the specimen with the strongest eGFP signal to prevent fluorescence 
saturation. Z-stacks for overview images and zoomed-in pictures for the organ of Corti and 
spiral ganglion neuron areas were obtained. 3D reconstruction with AMIRA was used to 
determine spiral ganglion neuron transfection more accurately.
Quantification of eGFP-expression
For in vitro data, the percentage of eGFP-positive inner (IHCs) and OHCs (OHCs) was 
manually quantified along the cochlea, by dividing the number of eGFP-positive cells by the 
total number of outer or inner hair cells per one or two 100 μm sections per basal and apical 
sample for each specimen. All visible spiral ganglion neurons in a cochlear explant were 
evaluated regarding their eGFP expression. The areas of the spiral limbus and supporting 
cells were assessed with a qualitative approach (as explained above, adjusted for each 
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experimental series) by means of a scale from 0 (no expression) to 3 (strongest signal). 
Control samples without AAV were used to exclude autofluorescence.
Immunological assays
Antibody titers against Anc80L65 in CSF and serum were determined through neutralization 
assays3. Using a 96-well format, heat-inactivated CSF or serum samples (collected as 
described above) were serially diluted in serum-free medium (Life Technologies, Carlsbad, 
CA), and then treated with Anc80L65-luciferase (106 GC/well) for 1 hour at 37 °C. The 
sample/Anc80L65-luciferase mix was then transferred onto HEK293 cells, which were 
treated with adenovirus (MOI 20) the day before. After 1 hour at 37 °C, diluted serum 
medium (1 part serum-free, 2 parts with serum) was added to each well. Two days later, the 
cells were treated with lysis buffer (Promega, Madison, WI) and frozen at −80 °C for 30 
minutes. The cells were then thawed at 37 °C for 15 minutes before being treated with 
substrate buffer (Tris-HCl, MgCl2, ATP [Life Technologies, Carlsbad, CA], D-Luciferin 
[Caliper Life Sciences, Hopkinton, MA]). Luminescence output was read using the Synergy 
BioTek Plate Reader (BioTek, Winooski, VT).
Hair cell electrophysiology
Cochleas were excised, mounted on glass coverslips and viewed on an Axio Examiner.A1 
upright microscope (Carl Zeiss, Oberkochen, Germany) equipped with a 63x water-
immersion objective and differential interference contrast optics. Electrophysiological 
recordings were performed at room temperature (22 °C–24 °C) in standard solutions 
containing (in mM): 137 NaCl, 5.8 KCl, 10 HEPES, 0.7 NaH2PO4, 1.3 CaCl2, 0.9 MgCl2, 
and 5.6 D-glucose, vitamins (1:100), and amino acids (1:50) as in MEM (Life Technologies, 
Carlsbad, CA) (pH 7.4; ~310 mOsm/kg). Recording electrodes (3–4 MΩ) were pulled from 
R-6 glass (King Precision Glass, Claremont, CA) and filled with intracellular solution 
containing (in mM): 140 CsCl, 5 EGTA-KOH, 5 HEPES, 2.5 Na2ATP, 3.5 MgCl2, and 0.1 
CaCl2 (pH 7.4; ~280 mOsm/kg). The whole-cell, tight-seal technique was used to record 
mechanotransduction currents using an Axopatch 200B (Molecular Devices, Sunnyvale, 
CA). Hair cells were held at −84 mV. Currents were filtered at 5 kHz with a low-pass Bessel 
filter, digitized at ≥20 kHz with a 12-bit acquisition board (Digidata 1440A, Molecular 
Devices, Sunnyvale, CA), and recorded using pCLAMP 10 software (Molecular Devices, 
Sunnyvale, CA). Hair bundles from IHCs and OHCs were deflected using stiff glass probes 
mounted on a PICMA chip piezo actuator (Physik Instrumente, Karlsruhe, Germany) driven 
by an LVPZT amplifier (E-500.00, Physik Instrumente, Karlsruhe, Germany) and filtered 
with an 8-pole Bessel filter (Model 3384 filter, Krohn-Hite Corporation, Brockton, MA) at 
40 kHz to eliminate residual pipette resonance. Stiff glass probes were designed to fit into 
the concave aspect of the array of hair cell stereocilia for whole-bundle recordings (3–4 μm 
diameter for OHCs and 4–5 μm diameter for IHCs). For the whole-cell electrophysiology 
recording at >P10, cochlea tissues were dissected at P5-7 and incubated in MEM(1X) + 
GlutaMAX™-I medium with 1% FBS at 37 °C, 5% CO2 for up to 30 days.
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Statistical tests
Descriptive statistics for in vitro and in vivo eGFP expression data are presented. Rotarod 
results were analyzed with a two-tailed t-test. Error bars, n values, and type of replicates for 
experiments are defined in the respective paragraphs and figure legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transduction of organotypic explant of murine cochlea with natural AAV serotypes 
and Anc80L65
Representative confocal projections of an in vitro comparison of several AAV serotypes for 
eGFP transgene expression in cochlear explants of C57BL/6 mice. A–G: Expression at the 
cochlear base for all serotypes, and apex and base for Anc80L65 after incubation with 1010 
genome containing (GC) particles for 48 hours. Scale bar = 100 μm. (Top: Myo7A+TuJ1, 
bottom: eGFP only, middle: overlay, S. Cells: Supporting Cells, OHC: Outer Hair Cell, IHC: 
Inner Hair Cell) H–K: Percentage of eGFP-positive hair cells per 100 μm after 48h or 48h+5 
days of incubation. Mean indicated by horizontal bar. Each condition had minimally N=3 for 
the 48h, and N=2 for the 48h+5d unless otherwise noted.
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Figure 2. In vivo cochlear transduction of natural AAV serotypes and Anc80L65
(A) Confocal images of mouse organs of Corti, counterstained with Alexa546-phalloidin 
(red) and imaged for eGFP (green). A total of 5 (AAV1), 4 (AAV2), 2 (AAV8), 1 (AAV6), 3 
(Anc80L65) C57BL/6 mice were injected with 1 μL of AAV stock solution in one ear at the 
titer indicated above each panel. Scale bar = 50 μm. Quantification of eGFP-positive IHCs 
(B) and OHC (C) in the base and apex of a representative AAV-eGFP injected cochlea for 
each vector. Quantification of eGFP-positive OHCs in the base and apex of AAV-eGFP 
injected cochleas. (D) Families of sensory transduction currents recorded at P7 (left) from 
eGFP-negative OHCs (black) and eGFP-positive OHCs (green). Hair bundles were deflected 
between −0.1 and 1 μm in 0.1 μm increments. Vertical scale bar indicates 200 pA; horizontal 
indicates 20 msec. Currents from eGFP-negative (black) and eGFP-positive (green) P35 
IHCs are shown on the right. Vertical scale bar indicates 100 pA; horizontal indicates 20 
msec. (E) Sensory transduction current amplitudes plotted for 103 IHCs and OHCs at the 
ages indicated at the bottom. Data from eGFP-negative (black) and eGFP-positive (green) 
are shown. The numbers of cells in each group are shown on the graph. All mice were 
injected at P1. (F) Mean ± standard deviation (SD). ABR thresholds plotted for four 
Anc80L65-injected ears (green) and four uninjected ears (black) together with data from one 
injected ear that had no eGFP fluorescence due to injection-related damage (red). (G) Mean 
± SD. DPOAE thresholds are plotted for four Anc80L65-injected ears (green) and four 
uninjected ears (black) and one negative control ear with injection damage without eGFP 
fluorescence (red). Injection titers for data points in B–G are as in A.
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Figure 3. Extensive Inner and Outer Hair Cell transduction in murine cochleas with Anc80L65
Low- (A) and high (B) magnification image of the entire apical portion of a mouse cochlea 
injected at P1 with 1 μL of Anc80L65-eGFP at 1.70 × 1012 GC/mL. The cochlea was 
harvested at P10 and stained with Alexa546-phalloidin (red) and imaged for eGFP (green). 
Scale bar = 100 μm in (A), 20 μm in (B). (C, D) Quantitative comparison of inner and outer 
hair cell transduction efficiency at an equal dose for all serotypes following round window 
injection of P1-2 C57BL/6 mice. Mouse cochleas in (C,D) were injected with 1.36 × 1012 of 
AAV1, AAV2, AAV8, and Anc80L65 and harvested at 7–9 days for live-cell imaging and 
quantification by epifluorescence microscopy (n=8 per group unless otherwise noted). Error 
bars represent SD. (E) Dose-dependency of Anc80L65 hair cell transduction. Cochleas 
exposed to two different Anc80L65-eGFP titers (1.80 × 1012 versus 1.36 × 1012 GC) were 
fixed and stained with Alexa546-phalloidin (red) and imaged for eGFP (green). Scale bar = 
20 μm.
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Figure 4. Anc80L65-eGFP transduction in vestibular sensory epithelia
(A) Mouse utricle from a P1 mouse injected with 1 μL Anc80L65-eGFP (1.7 × 1012 GC/
mL). The tissue was harvested at P10 fixed and stained with Alexa546-phalloidin (red) and 
imaged for eGFP (green). Morphological assessment across multiple focal planes of eGFP-
positive cells demonstrated transduction of stereotypical flask-shaped morphology of type I 
cells and the cylinder morphology of type II cells in every sample examined (not shown). 
Scale bar = 100 μm. (B) The crista of the posterior semicircular canal from the same mouse 
described for panel A. Scale bar = 50 μm. (C) The sensory epithelium of a human utricle. 
The tissue was exposed to 1010 GC Anc80L65.CMV.eGFP.WPRE for 24 hours, cultured for 
10 days, fixed, stained with Alexa546-phalloidin (red) and imaged for eGFP fluorescence 
(green). Scale bar = 100 μm. (D) High-magnification view of a human epithelium in the 
utricle stained with Alexa546-phalloidin (red) and Myo7A (blue) and imaged for eGFP 
(green) transduced in identical conditions as in C. White arrows in the overlay panel indicate 
selected eGFP-positive/Myo7A-positive cells. Scale bar = 20 μm.
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